Dr. Yancy poses an interesting question: Is heart failure a different disease in African Americans? He maintains that the heart failure population reflects a changing demographic, and nuances of disease manifestation and natural history in special populations must be appreciated. Recent studies reveal new data suggesting African Americans with heart failure benefit from the HYD/ISDN regimen when added to evidence-based therapy.
This presentation meets the needs of fellows-in-training, residents, cardiologists, and all attending physicians interested in the prevalence of heart failure in African Americans.
The intended result of this activity is increased knowledge. At the conclusion of this activity, participants will be able to
- Review the cardiovascular disease burden of special populations.
- Identify limitations of standard evidence-based practices for heart failure based on results of major clinical trials.
- Introduce a new paradigm of disease progression, i.e., nitric oxide homeostasis.
- Establish a biological rationale for nitric oxide enhancement.
- Discuss the results of the African American Heart Failure Trial and review its implications for clinical practice.
This presentation is designed for cardiologists, and all attending physicians interested in the prevalence of heart failure in African Americans.
Hospitalization for congestive heart failure. Explaining racial differences.
Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study.
Evaluation / Feedback
We value your comments; please send your suggestions and comments to the office of continuing medical education at the Texas Heart Institute.
Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Texas Heart Institute designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.
The estimated time to complete this activity, including review of the materials is 1 hour
Term of Approval
October 2005 through October 2008. Original release date: November 18, 2005.
In November 2005, this continuing medical education activity was reviewed by
James J. Ferguson III, MD, FACC Associate Director, Clinical Cardiology Research, THI and St. Luke’s Episcopal Hospital; Co-Chairman, Medical Education Committee, THI; Chairman, Research Committee, THI. Houston, Texas.
Disclosure of Relationships
It is the intent of the Texas Heart Institute to assure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program.
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed all relationships with any of the manufacturers of commercial products discussed or with either one or more of the corporate organizations offering educational grants for this continuing medical education activity.
Dr. Yancy is a consultant Scios, Inc, Medtronic, Inc, NitroMed, GlaxoSmithKlein, and CHF Solutions. He also receives research grant and research support from Scios, Inc, Medtronic, Inc, NitroMed, and GlaxoSmith Klein. He is a member of the Speaker’s Bureau for Novartis, Medtronic, Inc, NitroMed, and GlaxoSmithKlein.
Return to event home page.